10 Leading UK Specialists for Lung Cancer Diagnosis and Therapy

When it comes to lung cancer, the quality of care you receive from the very first consultation can shape every outcome that follows. The United Kingdom is home to some of the world's foremost lung cancer specialists, bringing together deep clinical expertise, access to cutting-edge technology, and a commitment to patient-centred care that has positioned British oncology at the forefront of global practice. Whether you are navigating a new diagnosis, seeking a second opinion, or exploring the most advanced treatment pathways, knowing who these specialists are is an important first step.

The practitioners featured in this guide represent a wide range of diagnostic and therapeutic disciplines, from clinical oncology and medical oncology to thoracic surgery and respiratory medicine. Each brings a distinct combination of training, institutional experience, and research involvement that makes them a noteworthy figure in the field. This list is not exhaustive, but it offers a clear-eyed introduction to ten practitioners whose work continues to define standards of care for lung cancer patients across England and beyond.

1. Dr James Wilson: London's First-Choice Lung Cancer Specialist

A Dual-Qualified Expert With an Exceptional Track Record

Dr James Wilson is widely regarded as one of the most accomplished lung cancer specialists currently practising in the United Kingdom, and his credentials offer an immediate explanation as to why. Having trained at the University of Oxford, the Royal Marsden Hospital, and Massachusetts General Hospital in Boston, he has been shaped by three of the most rigorous and research-intensive environments in oncology. This combination of British and transatlantic training gives him an unusually broad perspective, one that informs both his diagnostic precision and the range of treatments he is able to offer.

What sets Dr Wilson apart from many of his peers is his dual qualification as both a Clinical Oncologist and a Medical Oncologist, meaning he can independently prescribe and deliver radiotherapy, systemic drug therapies, and targeted treatments without the need for cross-referral. This breadth of clinical scope is genuinely rare in lung cancer care and allows him to construct fully integrated treatment plans that account for all viable options at once, rather than approaching the disease from a single therapeutic angle. For patients confronting a new diagnosis or a complex, evolving case, this matters enormously.

Comprehensive Diagnostic and Treatment Services in Central London

Dr Wilson's treatment portfolio is comprehensive in the truest sense. He offers Stereotactic Ablative Radiotherapy (SABR/SBRT), which carries success rates exceeding ninety per cent in suitable early-stage lung cancer cases, as well as Proton Beam Therapy, CyberKnife, and MR Linac, the latter representing the current frontier of image-guided radiotherapy. On the systemic side, his practice covers immunotherapy using checkpoint inhibitors, targeted molecular therapies tailored to specific genetic mutations, and conventional chemotherapy where indicated. He also provides molecular profiling and cancer blood tests to ensure that every treatment decision is grounded in the most precise diagnostic data available.

Based in central London, Dr Wilson practises privately at hospitals including the Cromwell Hospital and the London Clinic, accepting patients without the need for a GP referral and offering same-day or next-day consultations in many cases. This rapid-access model is particularly valued by patients whose circumstances do not allow for delays, or by those referred from across the UK and internationally for a specialist second opinion. Whether a patient presents with early-stage non-small-cell lung cancer or a Stage 4 diagnosis requiring urgent intervention, Dr Wilson's experience and infrastructure are demonstrably designed to meet them where they are.

2. Professor Sanjay Popat: Pioneering Thoracic Oncology at the Royal Marsden

A Clinician-Scientist at the Intersection of Research and Practice

Professor Sanjay Popat is a Consultant Medical Oncologist at the Royal Marsden Hospital in London, one of the most internationally recognised cancer centres in the world, and holds a concurrent research appointment at the Institute of Cancer Research. His clinical work focuses on thoracic malignancies, with particular emphasis on non-small-cell lung cancer and mesothelioma, and he has been an active contributor to international clinical trial design and oncology guideline development. The Royal Marsden consistently ranks among the top ten specialised oncology hospitals globally, and Professor Popat is a significant contributor to that standing.

His research interests centre on targeted therapy and the molecular biology of lung cancer, fields that have transformed the treatment of non-small-cell lung cancer in recent years. He has been involved in a number of landmark trials investigating novel drug combinations, resistance mechanisms, and biomarker-driven therapy selection, work that bridges the laboratory and the clinic in ways that benefit patients directly. For those with molecularly profiled lung cancers seeking access to emerging treatments, Professor Popat's dual role makes him a particularly well-positioned specialist.

Clinical Practice and Patient Benefits Within a World-Leading Institution

Patients referred to Professor Popat benefit not only from his individual expertise but from the full multidisciplinary infrastructure of the Royal Marsden, which includes specialist radiologists, thoracic surgeons, and dedicated lung cancer nursing teams working in close coordination. His patient caseload includes both standard and complex presentations, and his involvement in clinical trials means that eligible patients may gain access to treatments not yet available through conventional NHS or private pathways. This trial access can represent a meaningful advantage for patients whose disease has progressed through first-line or second-line standard therapies.

As a professor and educator, his influence extends beyond his direct patient base. The trainees and fellows who pass through his programme carry his approach to evidence-based, molecularly informed oncology into institutions across the country. This broader contribution to the specialty speaks well of his standing within the professional community and reinforces the depth of knowledge that underpins his day-to-day clinical practice.

3. Dr Tom Newsom-Davis: National Leadership and Thoracic Oncology at Chelsea and Westminster

Expert Clinical Practice Rooted in Evidence-Based Systemic Therapy

Dr Tom Newsom-Davis is a Consultant Thoracic Medical Oncologist at Chelsea and Westminster Hospital in London, a busy central London NHS trust with a well-established oncology service. He specialises in lung cancer and other thoracic malignancies, and his clinical practice reflects a strong grounding in the evidence base for systemic therapies, including immunotherapy and chemotherapy regimens used across the full staging spectrum of the disease. His approach is rooted in keeping current with rapidly evolving treatment guidelines, and he is recognised for his thoughtful, patient-informed decision-making.

Beyond his clinical work, Dr Newsom-Davis holds the position of Steering Committee Chair at the British Thoracic Oncology Group (BTOG), one of the UK's most active networks for thoracic cancer clinical trials and professional development. This role places him at the centre of national efforts to standardise and improve lung cancer care, and it gives him early visibility into the emerging evidence shaping future treatment protocols. Patients under his care benefit from a clinician who is not only practising at a high level but actively helping to define what best practice looks like across the NHS.

A Collaborative Clinician With a National Commitment to Improving Outcomes

Working within a multidisciplinary team environment, Dr Newsom-Davis coordinates closely with thoracic surgeons, clinical oncologists, and respiratory physicians to ensure that treatment plans reflect the full range of available options. His NHS base means that patients referred to him are typically working within a publicly funded pathway, while his expertise matches that of any private-sector counterpart. The institutional depth of a large London teaching hospital provides his patients with access to a broad range of diagnostic and support services under one roof.

His involvement with BTOG also means that he contributes to clinical trial design and recruitment, which can open doors for suitable patients to access novel therapies as part of well-structured research programmes. For patients seeking a lung cancer specialist in London's NHS sector who combines frontline clinical expertise with national-level leadership, Dr Newsom-Davis represents a well-regarded and thoroughly credentialled option.

4. Dr Jeremy Steele: A Nationally Recognised Authority on Lung Cancer and Mesothelioma

A Long-Standing Reputation in Thoracic Oncology and Rare Malignancies

Dr Jeremy Steele practises at HCA Healthcare UK, one of the country's largest private hospital groups, and has built a long-standing reputation as one of the UK's foremost experts in lung cancer and, in particular, malignant mesothelioma. The latter is a rare and aggressive cancer associated with asbestos exposure, and his level of specialism in this area places him among a very small number of UK clinicians with deep, hands-on expertise in its diagnosis and management. For patients facing this particularly difficult diagnosis, his accumulated experience is of considerable value.

His clinical background encompasses a wide range of systemic lung cancer therapies, and he has been involved in clinical research contributing to the evidence base for both lung cancer and mesothelioma treatment. He is well-regarded within the oncology community for his considered approach to staging and treatment planning, and his practice reflects a clear commitment to evidence-based care delivered within a high-quality private hospital environment. Patients benefit from the comprehensive diagnostic and therapeutic infrastructure that HCA's hospitals provide.

Private Practice Within a Well-Resourced Hospital Network

Practising within the HCA Healthcare UK network gives Dr Steele access to well-resourced facilities across London, with strong pathology, imaging, and multidisciplinary team support readily available. For patients seeking private care with rapid access to diagnostics and a clinician who carries genuine subspecialty depth in thoracic malignancies, his practice offers a credible and well-supported environment. His focus on patient outcomes is evident in how he navigates the complexity of cases that often arrive late-stage or with significant diagnostic uncertainty.

His specific expertise in mesothelioma is particularly relevant given how frequently this condition is misdiagnosed or delayed in its identification, partly due to its long latency period and partly because of its relative rarity. Clinicians of Dr Steele's experience in this area are comparatively few, and his availability within the private sector provides patients and families with a valuable route to specialist assessment and considered clinical guidance.

5. Dr Richard Lee: Respiratory Medicine and Early Lung Cancer Detection at the Royal Marsden

Championing Earlier Diagnosis Within a World-Leading Cancer Centre

Dr Richard Lee is a Consultant Physician in Respiratory Medicine at the Royal Marsden Hospital and holds a dedicated remit as its Champion for Early Cancer Diagnosis. This focus is significant in the context of lung cancer, where outcomes are strongly correlated with the stage at which the disease is identified. Five-year survival rates for Stage 1 lung cancer are dramatically higher than those for Stage 4, yet the majority of UK diagnoses still occur at an advanced stage. Dr Lee's work within this framework is aimed at shifting that clinical reality, both for his own patients and through the systems he helps to build and advocate for.

His background in respiratory medicine gives him a perspective that is somewhat distinct from that of a pure oncologist. Where a medical or clinical oncologist often enters the patient pathway after a confirmed diagnosis, Dr Lee is involved earlier, working at the diagnostic interface where symptoms are investigated, imaging is interpreted, and decisions about biopsy or onward referral are made. This skill set is increasingly valued as both the NHS and private sector seek to improve lung cancer detection at earlier, more treatable stages.

Diagnostic Expertise in the Context of Complex and Uncertain Presentations

For patients whose symptoms are ambiguous, whose imaging findings are equivocal, or who require specialist input to determine whether a pulmonary nodule warrants urgent investigation, Dr Lee's expertise is directly applicable. The Royal Marsden's resources mean that his diagnostic assessments are supported by some of the most advanced imaging technology and specialist pathology services in the country, enabling rapid, high-quality workup of suspected or confirmed lung cancers.

His dual identity as a respiratory physician and an early diagnosis champion means that he occupies a distinctive niche within the Royal Marsden's lung cancer service. Patients referred to him are typically at an earlier point in their diagnostic journey, and his ability to navigate that territory with both clinical rigour and institutional support makes him a valued point of entry within one of the UK's most respected cancer institutions.

6. Dr Merina Ahmed: Consultant Clinical Oncologist in Thoracic Cancer at the Royal Marsden

Delivering High-Quality Radiotherapy and Systemic Care for Lung Cancer

Dr Merina Ahmed is a Consultant Clinical Oncologist at the Royal Marsden Hospital, where her practice focuses on thoracic cancer including lung cancer and related malignancies. As a Clinical Oncologist, she is trained to deliver both radiotherapy and systemic therapies, giving her a broad treatment toolkit appropriate to the complexity of lung cancer management. She operates within the Royal Marsden's thoracic oncology multidisciplinary team, where decisions about staging, resectability, and treatment sequencing are made collaboratively with surgeons, medical oncologists, and radiologists.

Her work reflects the institutional standard of the Royal Marsden, which carries a global reputation for the quality and consistency of its oncology practice. For patients seeking NHS-based care at a world-class centre in London, or being seen through the Royal Marsden's private wing, Dr Ahmed's clinical oncology expertise represents an important part of the comprehensive service on offer. Her involvement in multidisciplinary decision-making ensures that patients receive treatment plans reviewed from multiple specialist perspectives.

A Clinician Embedded in a Multidisciplinary World-Class Team

One of the distinguishing features of care at the Royal Marsden is the depth of specialist involvement in each patient's journey, and Dr Ahmed's role is very much embedded within this ethos. Treatment plans developed within her team are informed by specialist radiology, nuclear medicine, pathology, and clinical trial access, all of which enhance the quality of care that reaches the patient. For patients with complex or ambiguous lung cancer cases, this level of multidisciplinary scaffolding provides a degree of confidence in decision-making that is difficult to replicate in smaller settings.

Dr Ahmed's contribution to the Royal Marsden's thoracic cancer service is both well-qualified and substantive. Her expertise in clinical oncology for thoracic malignancies ensures that radiotherapy planning and delivery, in particular, is handled with the precision and care that this modality demands when applied to tumours in proximity to critical thoracic structures. Patients referred into her clinic benefit from a specialist who is technically accomplished and institutionally well-supported.

7. Dr David Gilligan: Thoracic Oncology Specialist With a Commitment to Clinical Trials

A Thoracic Oncologist With Broad Experience in Lung Cancer Management

Dr David Gilligan is a specialist in Thoracic Oncology whose main clinical interests encompass lung cancer, mesothelioma, and thymic tumours. He holds an association with the UK Lung Cancer Coalition (UKLCC), an organisation that advocates for improved standards of lung cancer care across the United Kingdom, and his involvement reflects a commitment not just to individual patient care but to improving outcomes at a systemic level. His enthusiasm for clinical trial participation is well documented, and he actively involves eligible patients in research programmes that explore new treatment avenues.

His clinical background covers the full range of standard systemic treatments for lung cancer, including platinum-based chemotherapy regimens, newer immunotherapy agents, and targeted therapies for mutation-positive disease. His subspecialty interest in mesothelioma parallels that of a number of his UK colleagues, reflecting the continued prevalence of asbestos-related disease in British oncology clinics and the growing range of treatment options now available to these patients.

A Balanced Approach to Patient Care and Research Engagement

Dr Gilligan's involvement in clinical trials is a meaningful feature of his practice, particularly for patients who have exhausted standard treatment options or who are interested in accessing novel agents through well-supervised research pathways. His association with UKLCC also reflects a broader professional engagement with the systemic challenges of lung cancer care in the UK, including late diagnosis rates, inequalities in access to molecular testing, and gaps in the availability of targeted therapies across different parts of the country.

For patients seeking a thoracic oncologist who combines strong foundational clinical skills with a genuine research orientation and a sense of professional investment in the wider landscape of lung cancer care, Dr Gilligan presents a considered and credible option. His breadth of thoracic oncology experience means that patients with a range of diagnoses, not only lung cancer but also mesothelioma and rarer thoracic malignancies, may find his expertise relevant to their needs.

8. Dr Peter Dickinson: Advanced Radiotherapy and Lung Cancer Care at GenesisCare UK

Specialist Clinical Oncology With a Focus on Advanced Radiotherapy Techniques

Dr Peter Dickinson is a Consultant Clinical Oncologist at GenesisCare UK, where his specialist focus is lung cancer and advanced Stereotactic Ablative Body Radiotherapy (SABR). GenesisCare is one of the UK's largest specialist oncology networks, and Dr Dickinson's positioning within it reflects a practice built around the delivery of highly precise, image-guided radiotherapy in a well-equipped private setting. SABR has become an increasingly important modality in the management of early-stage lung cancer and oligometastatic disease, and his expertise in this area is aligned with one of the most significant recent developments in thoracic radiation oncology.

For patients who are not surgical candidates due to age, comorbidity, or patient preference, yet whose disease is technically amenable to radical treatment, SABR represents a compelling alternative to surgery. A skilled specialist in its delivery is a meaningful clinical asset, and Dr Dickinson's experience in this space makes him particularly relevant for patients in this category. The technical complexity of treating lung lesions with stereotactic precision requires both significant training and consistent procedural volume, and his practice is structured around exactly that.

Private Oncology Practice in a Well-Resourced Network Setting

GenesisCare's UK infrastructure provides Dr Dickinson with access to advanced radiotherapy planning and delivery technology, including the equipment and dosimetry expertise that SABR demands. Patients receiving care through GenesisCare benefit from a private pathway that prioritises clinical quality and scheduling efficiency, with shorter waiting times than are typically achievable through NHS radiotherapy services. This can be particularly relevant for early-stage lung cancer, where timely treatment initiation can influence outcomes.

Beyond SABR, Dr Dickinson's broader clinical oncology training means he is well-placed to advise on the full landscape of treatment options and to coordinate with colleagues in medical oncology and thoracic surgery where combination approaches are appropriate. His profile is that of a focused, technically skilled clinical oncologist whose practice is well-suited to patients seeking high-quality radiotherapy expertise within a private, specialist cancer care environment.

9. Dr Jaishree Bhosle: Medical Oncology and Systemic Lung Cancer Therapies at the Royal Marsden

A Medical Oncologist Specialising in Systemic Lung Cancer Treatment

Dr Jaishree Bhosle is a Consultant Medical Oncologist at the Royal Marsden Hospital, with a clinical focus on thoracic cancers. As a Medical Oncologist, her area of expertise is the prescription and management of systemic therapies, including chemotherapy, immunotherapy, and targeted agents for lung cancer patients. She works within the Royal Marsden's established thoracic oncology multidisciplinary team, which ensures that her clinical decisions are supported by the full breadth of the hospital's specialist resources, from advanced imaging to molecular pathology and clinical trial infrastructure.

Her practice encompasses both NHS and private patients at the Royal Marsden, a cancer centre that consistently places among the world's most respected oncology institutions. The depth of experience available within that environment, across different lung cancer subtypes, stages, and molecular profiles, means that patients seen by Dr Bhosle benefit not only from her individual expertise but from the collective knowledge embedded within the institution's long-standing approach to thoracic oncology.

Systemic Therapy Planning Within a Research-Active Centre

One of the hallmarks of care at the Royal Marsden is the integration of clinical trial access into routine oncological practice, and Dr Bhosle's work as a medical oncologist within that framework means her patients may have opportunities to access novel systemic agents through well-structured research pathways. For patients with molecularly defined lung cancers, particularly those with driver mutations such as EGFR, ALK, or ROS1, the availability of targeted therapies and emerging next-generation agents is an increasingly important part of the treatment conversation.

Dr Bhosle's role within a specialist thoracic oncology service at one of the UK's foremost cancer hospitals makes her a credible and well-supported choice for patients seeking medical oncology expertise within the Royal Marsden framework. Her focus on systemic treatment planning, combined with the institutional depth behind her practice, reflects a high standard of lung cancer care for those referred into her clinic.

10. Dr David Woolf: Consultant Clinical Oncologist at The Christie in Manchester

Thoracic Oncology Expertise at Europe's Largest Cancer Centre

Dr David Woolf is a Consultant Clinical Oncologist at The Christie NHS Foundation Trust in Manchester, the largest cancer centre in Europe and a consistently high-performing institution in both NHS and research contexts. A graduate of the University of Manchester, he has built a clinical practice focused on thoracic oncology including lung cancer. The Christie's scale and specialist depth mean that oncologists working within its thoracic team benefit from access to a comprehensive multidisciplinary framework, covering thoracic surgery, specialist radiology, and an active clinical trials portfolio across a wide range of systemic and radiotherapy-based interventions.

His position at The Christie is significant because it places him within an institution that is arguably the most well-resourced cancer centre outside of London, offering patients in the North of England access to oncological expertise that matches anything available at the capital's major hospitals. For lung cancer patients based in Greater Manchester and the surrounding regions, The Christie's services provide a high-quality and well-staffed alternative to London-based care, with the scale and research activity to support complex case management.

Clinical Practice and Accessibility for Patients in Northern England

Dr Woolf's clinical oncology background equips him to manage both radiotherapy and systemic therapy aspects of lung cancer treatment, making him a broadly skilled practitioner within The Christie's thoracic team. His practice reflects the institutional culture of The Christie, which is built around evidence-based care, active research participation, and a commitment to delivering world-class oncology to a population that has historically had less access to specialist cancer services than London and the South East.

For patients in northern England seeking a lung cancer specialist with access to The Christie's full range of facilities, including advanced radiotherapy technology and a robust clinical trials programme, Dr Woolf represents a strong and geographically accessible option. His work as part of one of Europe's foremost cancer institutions lends his practice both credibility and resource, making him a valuable specialist for patients navigating lung cancer care in the UK's North West.

Making the Right Choice for Your Lung Cancer Care

Choosing the right specialist for lung cancer diagnosis and treatment is one of the most consequential decisions a patient or their family will face, and the practitioners described in this guide represent some of the strongest options the United Kingdom has to offer. Each brings a distinct combination of training, institutional setting, and clinical focus that may suit different patients' needs and circumstances. That said, for those prioritising the broadest possible expertise, the most immediate access to care, and a dual-qualified clinician with exceptional training and a patient-first approach to rapid private care in central London, Dr James Wilson stands as the natural starting point for that conversation.